Determination of Anvisa aims to combat the indiscriminate use of medicines, which can bring problems to health
From now on, the sale of medicines to the weight loss It may only occur with the retention of medical revenue. The measure aims to control the use of the so -called weight loss “pens”, of which one of the most famous is the Ozempic.
The determination had been published by the National Health Surveillance Agency (Anvisa) In the Official Gazette (DOU). This happened on April 16 and the new standard would take effect 60 days after that, ie on Monday (23).
Brazil records more adverse events resulting from the use of the product
- Anvisa’s decision on the obligation to retention retention occurred after a pharmacovigilance analysis.
- This worked was based on data from an entity system that monitors side effects of drugs.
- Much more adverse events related to the use of these weight losses were identified outside the nominations approved by Anvisa in Brazil than abroad.
- Therefore, the directors of the agency understood that there is a need to protect the population from abusive use of these medications.
- New Nordisk, a pharmacist responsible for Ozempic, pointed out that “shares the same concerns of Anvisa regarding the irregular use of medicines.”
- The information is from G1.
read more
Indiscriminate use of medicines can cause problems
According to experts, indiscriminate use of Ozempic and similar drugs can result in product scarcity for those who really need it, such as patients with type 2 diabetes. In addition, it can cause severe malnutrition, muscle loss, intense hair loss and problems related to vitamins.
With medical follow -up, the lack of appetite is monitored, as well as the dietary pattern, preventing the patient from stop eating properly, for example. In addition, weight loss plateaus are accompanied to avoid frustrations, creating new strategies during treatment.
Cristina Schreiber, endocrinologist and director of the Department of Endocrinology of Sport and Exercise of the Brazilian Society of Endocrinology and Metabology (SBEM)
At the same time, excessive use of drugs reduces their effectiveness. This scenario ends up requiring increasing doses to reproduce the initial effect. Because of this, awareness of awareness of patients and society in general is required on the importance of responsible and oriented use of these products.
Obesity is a chronic, genetically inherited disease. Thus, during medical monitoring important decisions such as increasing, reducing the dose is made so that treatment becomes effective and sustainable over time.
Cristina Schreiber, endocrinologist and director of the Department of Endocrinology of Sport and Exercise of the Brazilian Society of Endocrinology and Metabology (SBEM)
Collaboration for the digital look
Alessandro Di Lorenzo has a degree in Journalism from the Federal University of Rio Grande do Sul (UFRGS) and has been working in the area since 2014. He worked on BandNews FM newsrooms in Porto Alegre and São Paulo.
